Richard Zelman MD | Current Advances and Clinical Trials

The field of cardiac cell therapy is rapidly evolving, with several ongoing clinical trials assessing the safety and efficacy of various cell-based approaches. Dr. Zelman points to some of the most promising studies:

 

The C-CURE Trial: This trial investigated the use of cardiac progenitor cells in patients with chronic heart failure. Results showed that patients who received cell therapy experienced significant improvements in heart function and exercise capacity compared to those who received standard care.

 

The CHART-1 Trial: This trial evaluated the safety and efficacy of cardiopoietic stem cells in heart failure patients. Although the primary endpoint was not met, a subgroup analysis suggested potential benefits in specific patient populations, underscoring the need for more targeted approaches.



Comments

Post a Comment

Popular posts from this blog

The Pioneering Work of Dr. Richard Zelman in Cardiology

  Richard Zelman MD , a renowned figure in cardiology, has long held that there's a profound link between the heart and mind, an interconnection that extends beyond the conventional understanding within his field. The heart, undoubtedly the pivotal organ in our physiology, is responsible for the circulation of oxygen-rich blood throughout the body, a process fundamental to our overall health. However, growing evidence underscored by Dr. Zelman's research and clinical experiences suggests that the relationship between our cognitive functions and cardiac health is far more intricate than previously thought. This article intends to delve deeper into this complex interplay, exploring the profound effects it has on our holistic well-being.
Read more

Lifeline: Sustaining hope for heart patients

  Dr. Richard Zelman    Cape Cod Hospital will continue to perform emergency angioplasties for the time being, but no longer as part of a Johns Hopkins study. State Department of Public Health officials will help to set up a registry for emergency angioplasty patients, said department spokesman Mark Leccese. Once that is established, Cape Cod Hospital and other community hospitals that had been part of the Johns Hopkins study can apply to participate in the registry, Leccese said. In the meantime, the four community hospitals can continue to perform the procedure on patients in the midst of heart attacks. "This is very good news for the people of Cape Cod, because it means a service we know is life-saving will be available here," said Deborah Dougherty, spokeswoman for Cape Cod Healthcare Inc., the parent company of Cape Cod and Falmouth hospitals. She said Cape Cod Hospital should not have any trouble getting on a registry. She said study results indicate emergency angio...
Read more

Dr. Richard Zelman

  Dr. Richard Zelman Dr. Zelman received his undergraduate degree from Duke University and his M.D from the University of Texas Health Science Center. He completed an Internship and Residency in Internal Medicine, followed by a clinical and research fellowship in Cardiovascular Medicine and a fellowship in Interventional Cardiology, all at Brigham and Women’s Hospital-Harvard Medical School. He is Board Certified in Internal Medicine, Cardiovascular Medicine, and Interventional Cardiology. In addition to practicing Cardiology and Interventional Cardiology at Cape Cod and Falmouth Hospitals, Dr. Zelman has cared for patients at Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, Tufts Medical Center, St. Elizabeth’s Hospital, and Boston University Hospital. Since joining the medical staff at Cape Cod Hospital in 1990, Dr. Zelman has been recognized as instrumental in developing the Cardiac Catheterization Laboratory, the Interventional Cardiology Service, the Cardiol...
Read more